Table 4.
Incidents Rates of Outcomes by MRA Use (New and Baseline Use Combined)
| Outcome | Overall (N=7012) | MRA Use | |
|---|---|---|---|
| Never Used (n=6432) | Baseline+New Use (n=580) | ||
| AF progression, No. (%) (N=6442)a | 1795 (27.86) | 1635 (27.81) | 160 (28.47) |
| All‐cause death | 785 (4.99) | 701 (4.79) | 84 (7.62) |
| Cardiovascular death | 301 (1.92) | 257 (1.76) | 44 (4.02) |
| Frist stroke, non‐CNS embolism, or TIA | 209 (1.35) | 198 (1.37) | 11 (1.01) |
| New‐onset HF (N=4947)b | 135 (1.21) | 123 (1.14) | 12 (3.00) |
| First cardiovascular hospitalization | 2146 (16.75) | 1946 (16.30) | 200 (22.94) |
Event rates per 100 patient‐years of follow‐up. CNS indicates central nervous system; TIA, transient ischemic attack.
a
Among the 6442 patients in the atrial fibrillation (AF) progression analysis, 562 were mineralocorticoid antagonist (MRA) users and 5880 were not.
b
Among the 4947 patients in the new‐onset heart failure (HF) analysis, 223 were MRA users and 4724 were not.